Nanjing Well Pharmaceutical Co Ltd Capital Reinvestment Ratio
Nanjing Well Pharmaceutical Co Ltd capital reinvestment ratio. Nanjing Well Pharmaceutical Co Ltd (603351) has a Capital Reinvestment Ratio of 0.15x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥69.51 Million) in capital expenditures (CN¥10.29 Million). Check cash flow reinvestment rate of Nanjing Well Pharmaceutical Co Ltd to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Nanjing Well Pharmaceutical Co Ltd (2014–2025)
Capital reinvestment ratio of Nanjing Well Pharmaceutical Co Ltd from 2014 to 2025. This chart tracks Nanjing Well Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 11 annual periods. Also explore 603351 net asset momentum to track the company's year-over-year net asset growth rate.
Nanjing Well Pharmaceutical Co Ltd Capital Reinvestment Ratio by Year (2014–2025)
Nanjing Well Pharmaceutical Co Ltd capital reinvestment ratio by year from 2014 to 2025. For the full cash flow conversion analysis, see 603351 cash generation efficiency.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.22x | CN¥238.24 Million | CN¥52.18 Million | ▼ -5.6% |
| 2024 | 0.23x | CN¥221.79 Million | CN¥51.46 Million | ▼ -61.8% |
| 2023 | 0.61x | CN¥120.24 Million | CN¥73.07 Million | ▼ -71.7% |
| 2022 | 2.15x | CN¥108.99 Million | CN¥233.90 Million | ▼ -29.1% |
| 2020 | 3.03x | CN¥93.30 Million | CN¥282.44 Million | ▲ +225.5% |
| 2019 | 0.93x | CN¥129.69 Million | CN¥120.62 Million | ▼ -22.9% |
| 2018 | 1.21x | CN¥63.76 Million | CN¥76.95 Million | ▲ +35.8% |
| 2017 | 0.89x | CN¥71.27 Million | CN¥63.35 Million | ▲ +64.4% |
| 2016 | 0.54x | CN¥128.18 Million | CN¥69.31 Million | ▼ -43.0% |
| 2015 | 0.95x | CN¥81.14 Million | CN¥76.92 Million | ▼ -20.1% |
| 2014 | 1.19x | CN¥74.62 Million | CN¥88.54 Million | — |